Sumatriptan 3  mg subcutaneous : Clinical relevance of acute treatment of migraine despite dose reduction

CONCLUSION: Clinical studies showed that reducing the subcutaneous dose to 3 mg in migraine treatment has significantly better tolerability with high response rates and freedom from pain within 2 h with 66.7% (3 mg) or 50% (6 mg).PMID:34557933 | DOI:10.1007/s00115-021-01189-8

Source: Der Nervenarzt - September 24, 2021 Category: Neurology Authors: Charly Gaul Stefanie F örderreuther Source Type: research